期刊文献+

阻抑骨髓移植受者白血病细胞免疫逃逸的实验研究

Experimental study on blocking immune escape of leukemia cells in the recipient after bone marrow transplantation
原文传递
导出
摘要 目的 了解转染小鼠可溶性Fas(sFas)基因后的骨髓移植 (BMT)能否阻抑白血病细胞的免疫逃逸 ,从而消灭残留白血病细胞、减少白血病复发。方法 经尾静脉向雌性C57BL 6小鼠体内植入EL4细胞 1 0 5个 只 ,建立移植性小鼠T细胞白血病 淋巴瘤模型。用转染sFas基因的腺病毒 (Ads Fas)感染 2 4h的雄性C57BL 6小鼠 (H 2 b)骨髓单个核细胞 ,对60 Co致死量照射的雌性同系小鼠进行BMT(D组 ) ,同时设立 :空白对照组 (A组 ,无骨髓细胞植入 )、常规BMT组 (B组 ,骨髓细胞未感染病毒 )、白血病组 (C组 ,仅输入EL4细胞 ,不进行照射和BMT)和绿色荧光蛋白 (EGFP)移植组 (E组 ,骨髓细胞感染AdEGFP)。观察各组造血重建情况、白血病 淋巴瘤的发生及小鼠生存率。结果 BMT后 1 0天脾指数检查 ,B、D、E三组之间差异无显著性 (P >0 .0 5) ,各组与A组间差异有显著性 (P <0 .0 1 )。移植后 30天外周血检查 ,B和D组恢复正常 ,C和E组白细胞和血小板均低下。 2个月后嵌合体检查存在Y染色体 ,骨髓细胞学检查B、D两组基本正常 ,C、E两组存在大量的瘤细胞。C组与E组死亡小鼠组织病理学显示脾脏等部位存在瘤细胞 ,而存活的B和D组小鼠基本正常。生存率 :A组全部死亡 ,B组 (6只 )和D组 (1 6只 )全部存活 ,C组存活 2只 (1 2 .5 % ) 。 Objective To investigate whether murine soluble Fas gen e transfected marrow graft could block the immune escape of leukemia cells, so as to eliminate the residual leukemia cells and reduce relapse after bone marrow t ransplantation(BMT).Methods The murine leukemia/lymphoma models were established by inoculating female C57BL/6 mice (H-2b) with 10 5 EL4 cell s/mouse through caudal vein. Donors of BM grafts were C57BL/6 male mice. Bone ma rrow mononuclear cells (BMMCs) wer e transfected with sFas or EGFP by adenovirus(adsFas or adEGFP) 24 hours before BMT(group D or E). The following three groups were set simultaneously: group A, no BMMCs transplanted; group B, BMMCs transplanted with no adenoviruses transfe ction; group C, EL4 cells transfusion only.Hematopoietic reconstitution, genera tion of leukemia/lymphoma and the survival rate were observed in all the groups after BMT.Results The spleen indices examined 11 days after BMT were not obviously different among group B, D and E (P>0.05), but in group A were significantly lower than those in the groups B, D, E( P<0 01). The leukocyte and platelet counts on day 30 after BMT were recovered in group B and D, but were very low in group C and E. The Y-chromosom es appeared 2 mon ths after BMT. Bone marrow pictures in group B and D were almost normal, but in group C and E had plenty of lymphoblast-like tumor cells. Tumors were obviously revealed in the mice of group C and E by histopathology examination, but did no t in group B and D. The survival rate was 0 in group A, 100% in group B and D, 1 2.5% in group C and 6.25% in group E. Compared with that in group E, the surviva l was significantly increased in the sFas group (P<0.01). Conclusions Graft transfected with sFas gene prolonged the post-BMT survival of leukemia/lymphoma mice. The transfection of sFas might block the ef fect of the immune escape of EL4 cells through FasL.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2003年第8期402-406,共5页 Chinese Journal of Hematology
基金 国家自然科学基金资助项目(39970708)
关键词 骨髓移植 白血病 免疫逃逸 FAS基因 Gene, Fas,soluble Bone marrow transplantation Leukemi a Immune escape
  • 相关文献

参考文献11

  • 1刘凌波,邹萍,徐之良,胡中波,龚非力.诱导H-2半相合小鼠骨髓受体获得免疫赦免的体内研究[J].中华器官移植杂志,2001,22(6):331-335. 被引量:1
  • 2Bremner TA, Chatterjee D, Hart Z, et al. THP-1 monocytic leukemia cells express Fas ligand constitutively and kill Fas-positive Jurkat cells.Leuk Res, 1999, 23: 865-870.
  • 3Lickliter JD, Krazke RA, Nguyen PL, et al. Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. Exp Hematol, 1999, 27: 1519-1527.
  • 4Buzyn A, Petit F, Ostankoviteh M, et al. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: a mechanism of tumor immune escape in leukemia patients. Blood, 1999, 94: 3135-3140.
  • 5Zeytun A, Hassuneh M, Nagarkatti M, et al. Fas-Fas ligand-based interactions between tumor cells and tumor specific cytotoxic T lymphocytes: a lethal two-way street. Blood, 1997, 90: 1952-1959.
  • 6Sykes M, Bukhaxi Z, Sachs DH. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation. Bone Marrow Transplant,1989, 4: 465-474.
  • 7Rensing-Ehl A, Frei K, Flury R, et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol, 1995, 25:2253-2258.
  • 8Finke J, Ferrone S, Frey A, et al. Where have all the T cells gone mechanisms of immune evasion by tumors. Immunol Today, 1999, 20:158-160.
  • 9Li JH, Rosen D, Sondel P, et al. Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells. Immunology, 2002, 105: 267-277.
  • 10Muruve DA, Barnes MJ, Stillman IE, et al. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Human Gene Therapy, 1999, 10: 965-976.

二级参考文献6

  • 1Duquesnoy RJ 李幼平.移植免疫生物学(第1版)[M].北京:科学出版社,2000.241-267.
  • 2Duquesnoy R J,移植免疫生物学,2000年,241页
  • 3张毅,中华血液学杂志,1999年,20卷,624页
  • 4巴德年,当代免疫学技术与应用,1998年,172页
  • 5何长民,器官移植免疫学,1995年,268页
  • 6张毅,唐佩弦,李秀森,江飞子,孙建民,毛宁.应用IRES序列研究人FL与Tpo基因在转染HFCL细胞中的表达[J].中华血液学杂志,1999,20(12):624-627. 被引量:5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部